Precision cancer drugs show promise for Kelun-Biotech
The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
BeiGene celebrates profit milestone on soaring drug sales
Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Key Takeaways: Global sales of the company’s…
No respite for RemeGen as problems and losses pile up
The developer of innovative drugs has sustained a series of blows to its finances, corporate partnerships, management team and star product, leaving investors jittery Key Takeaways: Despite rising revenue, RemeGen…
Junshi Biosciences Back in the Red, Pins Hopes on Covid Drugs
The innovative drug developer reported a first-quarter loss as a result of a steep drop in licensing revenue Key Takeaways: Junshi Biosciences’ revenue tumbled 61% in the first quarter, reflecting…
Recent Articles
BeiGene celebrates profit milestone on soaring drug sales
6160.HK
ONC.US
688325.SHG
No respite for RemeGen as problems and losses pile up
9995.HK
688331.SHG
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK -
BRIEF: Kelun-Biotech raises $250 million through share placement
6990.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
9939.HK
